TrialPLoS medicine2019

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Norberto Perico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.